Skip to content
Tuesday, June 10, 2025
Latest:
  • It’s a first: implementing safe and effective RSV prevention treatments significantly reduces hospitalizations in infants
  • Invisible to the naked eye: Space omics and the need for sample collection guidelines
  • What are nicotine pouches?
  • Learning that lifts us all: Insights from a year of growth and professional development
  • A novel source of genetic variation influencing childhood brain tumors
Baylor College of Medicine Blog Network

  • Home
  • Momentum
    • About Momentum
    • Resources
    • Contributors
      • Taylor Barnes
      • Dana Benson
      • Molly Chiu
      • Julie Garcia
      • Graciela Gutierrez
      • Anna Kiappes
      • Andy Phifer
      • Homa Shalchi
      • Melissa Tucker
    • Contact Us
  • From The Labs
    • About From the Labs
    • Follow From The Labs on Twitter
  • Policywise
    • About PolicyWise
    • Follow @BCMEthics on Twitter
  • The Stitch
    • About The Stitch
  • Progress Notes
    • About Progress Notes
    • Progress Notes Editors
    • Connect With Us
  • bcm.edu
From The Labs

Clinical trial finds that oral drug MK-0616 substantially reduces ‘bad’ cholesterol

March 14, 2023 atherosclerosis,  bad cholesterol,  Cardiovascular Disease,  LDL-cholesterol,  MK-0616,  PCSK9 inhibitor,  Research

MK-016 could offer another potential option to achieve guideline-recommended LDL-C levels resulting in reduction of cardiovascular risk.

Read More

From the Labs: Image of the Month

Blood vessels (magenta) intertwined with metastatic medulloblastoma tumor cells (green) nestled within the protective layers that surround the mouse spinal cord. From the Labs: a closer look at metastatic medulloblastoma

Healthy Habits: A DOC-umentary Series

https://www.youtube.com/watch?v=SlNiMWHUhbc

Archives

Search

©1998 - 2023 Baylor College of Medicine®
One Baylor Plaza, Houston, Texas 77030
(713) 798-4951